| Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/35260458_HAS_TOPIC_C0001675> <https://research.tib.eu/covid-19/entity/35260458_HAS_TOPIC_C0008059> <https://research.tib.eu/covid-19/entity/35260458_HAS_TOPIC_C0013178> <https://research.tib.eu/covid-19/entity/35260458_HAS_TOPIC_C0020972> <https://research.tib.eu/covid-19/entity/35260458_HAS_TOPIC_C0043444> <https://research.tib.eu/covid-19/entity/35260458_HAS_TOPIC_C0086287> <https://research.tib.eu/covid-19/entity/35260458_HAS_TOPIC_C0086418> <https://research.tib.eu/covid-19/entity/35260458_HAS_TOPIC_C0206006> <https://research.tib.eu/covid-19/entity/35260458_HAS_TOPIC_C0282461> <https://research.tib.eu/covid-19/entity/35260458_HAS_TOPIC_C0282687> <https://research.tib.eu/covid-19/entity/35260458_HAS_TOPIC_C5203670> <https://research.tib.eu/covid-19/entity/35260458_HAS_TOPIC_C5392141>
?:authorAffiliation	[\'London School of Hygiene & Tropical Medicine, London, UK deborah.Watson-Jones@lshtm.ac.uk.\', \'Mwanza Intervention Trials Unit, Mwanza, Tanzania, United Republic of.\', \'L\'Institut National de Recherche Biomédicale, Goma, Democratic Republic of the Congo.\', \'Epicentre, Paris, Île-de-France, France.\', \'MSF, Paris, France.\', \'London School of Hygiene & Tropical Medicine, London, UK.\', \'Janssen Vaccines and Prevention BV, Leiden, Zuid-Holland, The Netherlands.\', \'Coalition for Epidemic Preparedness Innovations, Oslo, Norway.\', \'UK Public Health Rapid Support Team, Public Health England and LSHTM, London, UK.\', \'L\'Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.\']
?:citedBy	-1
?:creator	<https://research.tib.eu/covid-19/entity/Ahuka_Steve> <https://research.tib.eu/covid-19/entity/Bausch_Daniel_G> <https://research.tib.eu/covid-19/entity/Camacho_Anton> <https://research.tib.eu/covid-19/entity/Choi_Edward_M> <https://research.tib.eu/covid-19/entity/Douoguih_Macaya> <https://research.tib.eu/covid-19/entity/Edmunds_W_John> <https://research.tib.eu/covid-19/entity/Edwards_Tansy> <https://research.tib.eu/covid-19/entity/Grais_Rebecca_F> <https://research.tib.eu/covid-19/entity/Hatchett_Richard> <https://research.tib.eu/covid-19/entity/Kavunga-Membo_Hugo> <https://research.tib.eu/covid-19/entity/Lees_Shelley> <https://research.tib.eu/covid-19/entity/Leyssen_Maarten> <https://research.tib.eu/covid-19/entity/Luhn_Kerstin> <https://research.tib.eu/covid-19/entity/Muyembe_Jean-Jacques> <https://research.tib.eu/covid-19/entity/Roberts_Chrissy_H> <https://research.tib.eu/covid-19/entity/Roberts_Natalie> <https://research.tib.eu/covid-19/entity/Spiessens_Bart> <https://research.tib.eu/covid-19/entity/Watson-Jones_Deborah>
?:doi	<https://research.tib.eu/covid-19/entity/10.1136/bmjopen-2021-055596>
?:doi	10.1136/bmjopen-2021-055596
?:hasPublicationType	<https://research.tib.eu/covid-19/entity/Clinical_Trial_Protocol> <https://research.tib.eu/covid-19/entity/Journal_Article> <https://research.tib.eu/covid-19/entity/Research_Support%2C_Non-U.S._Gov%27t>
?:journal	BMJ open
is ?:pmid of	<https://research.tib.eu/covid-19/entity/35260458>
?:pmid	<https://research.tib.eu/covid-19/entity/35260458>
?:pmid	35260458
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/Covid-19>
?:rankingScore_SJR	1.372
?:rankingScore_hIndex	57
?:title	Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo.
?:type	<https://research.tib.eu/covid-19/vocab/Publication> <https://research.tib.eu/covid-19/vocab/Publication_Author>
?:year	2022

Property

Value

is ?:annotates of

?:authorAffiliation

[\'London School of Hygiene & Tropical Medicine, London, UK deborah.Watson-Jones@lshtm.ac.uk.\', \'Mwanza Intervention Trials Unit, Mwanza, Tanzania, United Republic of.\', \'L\'Institut National de Recherche Biomédicale, Goma, Democratic Republic of the Congo.\', \'Epicentre, Paris, Île-de-France, France.\', \'MSF, Paris, France.\', \'London School of Hygiene & Tropical Medicine, London, UK.\', \'Janssen Vaccines and Prevention BV, Leiden, Zuid-Holland, The Netherlands.\', \'Coalition for Epidemic Preparedness Innovations, Oslo, Norway.\', \'UK Public Health Rapid Support Team, Public Health England and LSHTM, London, UK.\', \'L\'Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.\']

?:citedBy

-1

?:creator

?:doi

<https://research.tib.eu/covid-19/entity/10.1136/bmjopen-2021-055596>

?:doi

10.1136/bmjopen-2021-055596

?:hasPublicationType

?:journal

BMJ open

is ?:pmid of

<https://research.tib.eu/covid-19/entity/35260458>

?:pmid

<https://research.tib.eu/covid-19/entity/35260458>

?:pmid

35260458

?:publication_isRelatedTo_Disease

<https://research.tib.eu/covid-19/entity/Covid-19>

?:rankingScore_SJR

1.372

?:rankingScore_hIndex

?:title

Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo.

?:type

?:year

2022

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/35260458>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/35260458>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

Metadata